文献速递消化道肿瘤与早癌消化内镜

巴雷特食管监测与按需内镜研究(BOSS):一项随机对照试验

Barrett's Oesophagus Surveillance Versus Endoscopy at Need Study (BOSS): A Randomized Controlled Trial.
PubMed 文献 · Gastroenterology · 2025-04-01

BOSS研究在英国109个中心将3453例巴雷特食管患者随机分为每2年监测内镜组(1733例)和按需内镜组(1719例),中位随访12.8年。监测组与按需组总生存无差异(HR 0.95,95%CI 0.82-1.10,P=0.503),癌特异性生存、食管腺癌诊断时间及分期也无差异。作者认为按需内镜可能是低危患者的安全替代方案。

要点

  • 监测内镜未改善巴雷特食管患者的总生存或癌特异性生存。
  • 监测组与按需组总生存无差异(HR 0.95,95%CI 0.82-1.10,P=0.503)。
  • 按需内镜可能是低危患者的安全替代方案。

核心结论

  • 监测内镜未改善总生存或癌特异性生存,按需内镜可能是低危患者的安全替代方案。

研究设计与样本

  • BOSS为在英国109个中心开展的随机对照试验,将巴雷特食管患者随机分为每2年监测内镜组或按需内镜组(仅因症状提供内镜),随访至少10年。
  • 共招募3453例患者,监测组1733例,按需组1719例,主要结局为意向性治疗人群的总生存。

主要发现

  • 主要结局中位随访12.8年,监测组1733例中333例死亡,按需组1719例中356例死亡,总生存无差异(HR 0.95,95%CI 0.82-1.10,分层log-rank P=0.503)。
  • 癌特异性生存无差异:监测组108例死于任何癌症,按需组106例(HR 1.01,95%CI 0.77-1.33,P=0.926)。
  • 食管腺癌诊断时间无差异:监测组40例、按需组31例诊断为食管腺癌(HR 1.32,95%CI 0.82-2.11,P=0.254),诊断时癌症分期也无差异。
  • 严重不良事件:监测组8例(0.46%),按需组7例(0.41%)。

临床怎么用

  • 作者认为按需内镜可能是低危患者的安全替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Barrett's esophagus (BE) is a precursor lesion for esophageal adenocarcinoma (EAC). Surveillance endoscopy aims to detect early malignant progression; although widely practiced, it has not previously been tested in a randomized trial. METHODS: BOSS (Barrett's Oesophagus Surveillance Versus Endoscopy at Need Study) was a randomized controlled trial at 109 centers in the United Kingdom. Patients with BE were randomized to 2-yearly surveillance endoscopy or "at-need" endoscopy, offered for symptoms only. Follow-up was a minimum of 10 years. The primary outcome was overall survival in the intention-to-treat population. Secondary outcomes included cancer-specific survival, time to diagnosis of EAC, stage of EAC at diagnosis, frequency of endoscopy, and serious adverse events related to interventions. RESULTS: There were 3453 patients recruited; 1733 patients were randomized to surveillance and 1719 to at-need endoscopy. Median follow-up time was 12.8 years for the primary outcome. There was no evidence of a difference in overall survival between the surveillance arm (333 deaths among 1733 patients) and the at-need arm (356 deaths among 1719 patients; hazard ratio, 0.95; 95% CI, 0.82-1.10; stratified log-rank P = .503). There was no evidence of a difference for surveillance vs at-need endoscopy in cancer-specific survival (108 vs 106 deaths from any cancer; hazard ratio, 1.01; 95% CI, 0.77-1.33; P = .926), time to diagnosis of EAC (40 vs 31 patients had a diagnosis of EAC; hazard ratio, 1.32; 95% CI, 0.82-2.11; P = .254), or cancer stage at diagnosis. Eight surveillance patients (0.46%) and 7 at-need patients (0.41%) reported serious adverse events. CONCLUSIONS: Surveillance did not improve overall survival or cancer-specific survival. At-need endoscopy may be a safe alternative for low-risk patients. (ClinicalTrials.gov, Number: NCT00987857.).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Old O, Jankowski J, Attwood S, et al. Barrett's Oesophagus Surveillance Versus Endoscopy at Need Study (BOSS): A Randomized Controlled Trial. Gastroenterology. 2025. PMID: 40180292. doi:10.1053/j.gastro.2025.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。